Apremilast in Refractory Alopecia Areata.

ABSTRACT: Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast.

SUBMITTER: Estebanez A 

PROVIDER: S-EPMC6830030 | biostudies-literature | 2019 Sep-Oct

REPOSITORIES: biostudies-literature